PFEPFIZER INC
Pharmaceutical Preparations
- Revenue
- $62.6B
- 1.6% YoY
- Operating margin
- —
- EBITDA
- —
- Market cap
- $174.0B
- Employees
- 75,000
- $834K revenue each
- Net debt / EBITDA
- —
- $3.0B net debt
- AI in 10-K
- 3.8
- mentions per 10K words
Takeover score 0 of 13
Fixable underperformance 0 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo—Median CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo151% of net incomeCash flow under 80% of net income
- Dilutive SBCNo1% of revenueOver 10% of revenue
- Payouts exceed cash flowNo0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo36% of assetsOver 40% of assets
- Shareholder dissentNo—Any vote under 80% support
Buyer economics 0 of 4
- Low revenue per employeeNo$834K · 68th pctBottom quartile of its SIC industry
- Quiet on AINo3.8 per 10K words · 77th pctBottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedNo$174.0B market capMarket cap $500M–$5B
Catalysts 0 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo$3M netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $73.6B | $91.8B | $50.9B | $63.6B | $62.6B | 1.6% |
| Net income | $22.0B | $31.4B | $2.1B | $8.0B | $7.8B | 3.2% |
| Operating cash flow | $32.6B | $29.3B | $8.7B | $12.7B | $11.7B | 8.2% |
| Capex | $2.7B | $3.2B | $3.9B | $2.9B | $2.6B | 9.6% |
| Stock-based comp | $1.2B | $872M | $525M | $877M | $799M | 8.9% |
| Buybacks | $0 | $2.0B | $0 | $0 | — |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $3M · 3
- Open-market sells, 12 mo
- $135K · 2
- Net
- $3M
Pay vs performance
No pay-versus-performance disclosure yet.